Beijing SL Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002038.SZ

Beijing SL Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) on January 27, 2025: 6.67

Beijing SL Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) is 6.67 on January 27, 2025, a -24.29% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Beijing SL Pharmaceutical Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 9.46 on March 18, 2024, which is 41.91% above the current Price to Sales Ratio (P/S).
Beijing SL Pharmaceutical Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 6.32 on September 18, 2024, which is -5.21% below the current Price to Sales Ratio (P/S).
Beijing SL Pharmaceutical Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 7.68.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shenzhen Stock Exchange: 002038.SZ

Beijing SL Pharmaceutical Co., Ltd.

CEO	Dr. Mingbo Xu Ph.D.
IPO Date	Sept. 9, 2004
Location	China
Headquarters	Building 1, Bitongyuan
Employees	856
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, researches, develops, produces, and markets genetic engineering and related drugs in the People's Republic of China and internationally. The company's finished formulations includes temozolomide; arsenic trioxide; lenalidomide; docetaxel; paclitaxel; filgrastim Recombinant human granulocyte colony-stimulating factor; recombinant human interleukin-11; recombinant human interleukin-2; thymopentin; vinorelbine bitartrate; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; ciclosporin; mycophenolate mofetil dispersible; ornidazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; ademetionine 1,4-butanedisulfonate; glutathione; enoxaparin sodium; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; risedronate sodium; loratadine dispersible; somatostatin; octreotide acetate; calcitonin (salmon); paracetamol and tramadol hydrochloride; and etodolac. It also offers active pharmaceutical ingredients. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is based in Beijing, the People's Republic of China.

Key trends

Past 5 years